The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration (FDA) has requested the removal of information regarding the risk of suicidal ideation and behaviors (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications.
The US Food and Drug Administration has approved Prolivâ„¢Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration has approved Prolivâ„¢Rx, a novel at-home neuromodulation therapy as adjunctive treatment for adults with major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved the first at-home transcranial direct current stimulation (tDCS) device for the treatment of moderate to severe major depressive disorder (MDD).
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved lumateperone (CAPLYTA®) as an adjunctive therapy with antidepressants for the treatment of major depressive disorder (MDD) in adults.
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) has approved risperidone (Uzedy) as a once-monthly extended-release injectable suspension for the treatment of bipolar I disorder (BD-I).
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD). Â
The US Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted not to recommend the use of brexpiprazole in combination with sertraline for the treatment of posttraumatic stress disorder (PTSD). Â
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic, according to recent...
Clozapine was more effective than olanzapine and amisulpride in first-episode psychosis (FEP) patients with schizophrenia, schizophreniform, or schizoaffective disorder who did not respond to an initial antipsychotic, according to recent...
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
A new cohort study published in JAMA Psychiatry examined whether real-world antidepressant prescription patterns in MDD patients could help identify biologically meaningful subtypes of depression.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
The integration of physical activity into routine psychiatric care could significantly improve outcomes for people with severe mental illness (SMI), including schizophrenia, according to a narrative review published in JAMA Psychiatry.
Loneliness significantly contributes to the relationship between anxiety symptoms, depressive symptoms, and suicidal ideation among US adults, according to recent analysis findings.
Loneliness significantly contributes to the relationship between anxiety symptoms, depressive symptoms, and suicidal ideation among US adults, according to recent analysis findings.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
Patients with migraine are at 2 times the risk for depression or anxiety compared to those without migraine, according to a large nationwide Swedish cohort study published in The Journal of Headache and Pain.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
A clinical decision-support system called PETRUSHKA was found to improve antidepressant continuation in adults with major depressive disorder (MDD). The tool also improved depression and anxiety symptoms.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
Increased copy number variant (CNV) burden, specifically deletions, is associated with earlier age at onset (AAO) of schizophrenia, according to recent research findings.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
A comprehensive economic evaluation reported substantial national and state-level societal costs of schizophrenia in the United States for the 2024 calendar year, estimating a total excess societal cost at $366.8 billion.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
The FDA has approved milsaperidone for the treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults.
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
A synthetic form of psilocybin (COMP360) has met the primary endpoint in a second phase 3 trial evaluating its efficacy and safety in patients with treatment-resistant depression (TRD).
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
Andrew Penn, MS, PMHNP, discusses the recent vote by the FDA's advisory committee (PDAC) against an MDMA-based therapy for the treatment of PTSD in adults and sheds light on what this means for the future of PTSD treatment.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
In this insightful discussion, Brittany Albright, MD, MPH, Co-Chair, Psych Congress Elevate, offers a comprehensive overview of the role that deprescribing plays in effective psychiatric care.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
Chelsie Monroe, APN, PMHNP-BC, discusses practical screening strategies, including the use of the Epworth Sleepiness Scale, the importance of collaboration with sleep specialists, and the clinical relevance of the orexin system.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
In this video, Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, offers several practical considerations for mental health care providers contemplating the use of AI in psychiatric practice.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Edward Kaftarian, MD, Steering Committee, Psych Congress, provides an update on the current state of HIPAA requirements for clinicians practicing via telehealth.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
Psych Congress Co-Chair Greg Mattingly, MD, breaks down the key pharmacologic differences between the US Food and Drug Administration (FDA)-approved vesicular monoamine transporter 2 (VMAT-2) inhibitors for the treatment of TD.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Psych Congress Steering Committee Member Steven Chan, MD, MBA, FAPA, FAMIA, offers an overview of the most pressing topics in digital mental health.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video, Michael Asbach, DMSc, PA-C, walks clinicians through some key clinical considerations for navigating diagnostic ambiguity when assessing patients for bipolar II disorder.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
In this video filmed at Psych Congress 2025, Steering Committee member Desiree Matthews, PMHNP-BC, discusses the ways in which digital tools can be leveraged to reduce provider burnout.
Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN
Featuring Andrew Penn, MS, PMHNP...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
